by the GP and the remote dermatologist, and the image quality were also assessed in each study group.
The most common lesion examined by teledermatology was seborrheic keratosis (29.2%, n ¼ 73), followed by common acquired melanocytic nevus (26.8%, n ¼ 67). Basal cell carcinoma was the most common malignant lesion diagnosed (6.4%, n ¼ 16), followed by squamous cell carcinoma (4%, n ¼ 10). Thus, 10.4% (n ¼ 26) of patients were referred because of malignant lesions. In the overall series, 60.8% and 76.8% of the CTC and CTC1DTC groups, respectively, were not referred to the skin cancer clinic (P ¼ .001). The subanalysis of patients having pigmented lesions increased this nonreferral percentage to 69.39% and 89.13%, respectively (P ¼ .001). The average time spent by the operating GPs was 7.44 minutes for CTC patients and 8.7 minutes for CTC1DTC patients (P ¼ .01). The time spent by the dermatologist in the evaluation of CTC or CTC1DTC patients was 1.04 minutes and 1.22 minutes, respectively (P ¼ .14). The percentage of cases with the highest DCL (DCL¼3) was 61.6% in the CTC group and 79.2% in the CTC1DTC group (P ¼ .001). The frequency of low-quality pictures was 3.2% and 1.6% in the CTC and CTC-DTC groups, respectively (P ¼ .41). The results of the diagnostic performance study are listed in Table I .
The interim results of this prospective randomized and blinded study provide meaningful favorable data ahead of the definitive results of a large-scale study on the effect of the addition of dermoscopic images to the routine internet-based skin cancer triage. 
Lara

Frequency of total body skin examinations among US dermatologists
To the Editor: Skin cancer is the most common cancer in the United States with increasing rates of both melanoma and nonmelanoma skin cancers. 1,2 The US Preventive Services Task Force states that there is insufficient evidence to assess the benefits and harms of total body skin examination (TBSE) by primary care physicians, whereas the American Academy of Dermatology and the American Cancer Society encourage routine TBSE, especially for those at high risk. 3, 4 This study aimed to clarify the frequency with which dermatologists perform TBSE.
Surveys were sent by e-mail to US dermatologists in February 2015. Respondents were asked how often they performed TBSE in patients with no personal or family history of skin cancer and those with a high risk for skin cancer ( family history of skin cancer; personal history of sunburns, actinic damage, dysplastic nevi, and/or multiple nevi; or fair skin). Participant demographic data were collected including years in practice, location of practice (rural, suburban, urban, or combination), and practice environment (residency training, academic faculty practice, private practice, outpatient-based hospital clinic, or other). Data were analyzed using standard 2 and 95% confidence intervals.
Of 6500 dermatologists surveyed, 9.6% (623) responded. The literature supports that our study sample size appears to be large enough to make accurate statistical inferences and representative of the surveyed population. In patients with no personal or family history of skin cancer, 86% of dermatologists reported performing TBSE either annually or every 2 to 3 years, 1% of dermatologists reported performing TBSE every 6 months, and 13% of dermatologists reported rarely/never performing TBSE routinely in this population. 5 In comparison, in patients with high risk for skin cancer, 60% of dermatologists reported performing TBSE annually, with 34% performing TBSE every 6 months. In addition, in the high-risk population, 4% performed TBSE every 3 to 4 months, 2% performed TBSE every 2 to 3 years, and 1% of dermatologists reported rarely or never performing TBSE.
The majority of dermatologists reported screening patients by TBSE at least every 2 to 3 years if not annually. In addition, those at increased risk of skin cancer were predominantly screened at least annually, if not every 6 months. Screening frequency was not associated with dermatologist gender, practice location, number of years in practice, or practice environment, with the exception of female practitioners and younger providers (with \5 years of practice experience) who screened those at normal risk for skin cancer more frequently (P ¼ .00004 and P ¼ .004, respectively).
Limitations of this study include selection bias, as those who responded to this survey may have been more interested in this topic, recall bias, which may account for inaccuracy or incompleteness of participant's responses, and finally systemic bias through which participants may have reported more screening than actually performed.
There are no national guidelines regarding frequency of routine TBSE. This survey suggests that the majority of dermatologists routinely perform TBSE in patients at low risk every 2 to 3 years and more frequently in patients at high risk. These data suggest a uniform practice of skin cancer screening in the United States across the broad and diverse population of dermatologists. A systematic review of comorbidity indices used in the nonmelanoma skin cancer population
To the Editor: Nonmelanoma skin cancer (NMSC) is more common than all other cancers combined in the United States, and despite low mortality, their management is associated with significant cost. Questions have been raised regarding appropriate treatment in patients with limited life expectancy, and the best way to determine which patients fall into this category. 1 Prioritizing comorbidity rather than age may be preferred for informing treatment decisions in the very elderly.
A systematic review of the literature was conducted to identify comorbidity instruments used in the NMSC population. Squamous and basal cell carcinoma were included, whereas Merkel cell
